Clinical ink, a global life science technology company, today announced that experienced healthcare industry veteran Dr. Jonathan Goldman MD has joined the company as Chief Executive Officer (CEO). Jonathan succeeds Ed Seguine who has led Clinical ink since nearly fourteen years ago.
Nature Magazine Publishes Work Demonstrating Clinical ink Technology Sensitivity to Parkinson’s Disease
COA vs. eCOA Cost Calculator
Breakthrough Evidence with Digital Biomarkers in Movement Disorders
as it happens,
from any source.
Deloitte Technology Fast 500™
2021 and 2022 Award Recipient for Fastest-Growing Companies in North America.
Clinical ink is leading the way to recenter decentralized clinical trials by connecting data and operations.
At the core of our clinical trial solutions is the Clinical ink eSource ecosystem, designed to ingest all incoming data into a unified data platform that supports analytics within and across studies, regardless of how it was captured or by whom.
A Better eSource Solution
Clinical ink’s eSource methods integrate Direct Data Capture (DDC) technology and electronic Clinical Outcome Assessments (eCOA) for a wide range of phases and therapeutic areas.
The result is faster, higher-quality clinical trial data. Our eSource solutions ingest data from multiple sources, facilitating decentralized trials and shifting the industry towards capturing data directly from the patient.
eSource Technology and Solutions
Simplify and speed study startup, standardize processes, and empower patients.
Sensors & Wearables
Enrich advanced clinical trial data collection with a variety of sensors and wearables solutions.
Validate measurements from sensors, algorithms, and deliver clinical data in real-time.
See everything our eSource technology platform has to offer.
eSource technologies improve the efficiency and reduce the cost of clinical trials, particularly in the context of complex therapeutic areas.
The depth and breadth of our therapeutic experience – across neurology, infectious disease, immunology, and oncology – means you get the expertise and improved results for your clinical research.
Improve results for complex clinical trials involving central nervous system conditions.
Speed up trial timelines and improve the data quality of your infectious disease studies.
Leverage eSource tools to simplify and improve outcomes in complex Lupus clinical trials.
Deliver on the Enhancing Oncology Model and improve patient adherence throughout the trial.